BIONEXUS GENE LAB CORP
BGLCNASDAQ🏆 #3900 by market capUS Equity
$1.32▼ $0.19 (−14.29%)
Live1h—
24h▼ 14.3%
7d—
14d—
30d—
1y—
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
-67.1%
Declining
📊Gross Margin
12.2%
Thin
💵FCF Margin
31.5%
Strong
⚖️P/S Ratio
1.2x
Cheap
Otter Score
51
Weak
No chart data available for BGLC.
Trading Snapshot
- Day Range
- $1.31 – $1.34
- 52-Week Range
- $1.07 – $6.10
- Volume
- $1.65B
- Avg Volume
- $2.01B
- Shares Outstanding
- 2.4M
- Next Earnings
- Oct 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $786,439
- P/E Ratio
- —
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-1.47
- Dividend Yield
- —
Why Investors Own BGLC
- ✓High-growth profile — revenue up +20.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$3M▲ +23.5% YoY
Gross Margin (TTM)
26.8%▲ +3.4% YoY
Operating Income (TTM)
$695,511▲ +23.5% YoY
Free Cash Flow (TTM)
$283,695▲ +23.5% YoY
About BIONEXUS GENE LAB CORP
A company profile for BIONEXUS GENE LAB CORP isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
51/100
Analyst Price Target
ⓘAverage Target
$1.73
▲ +30.8% Upside
High Target$2.07
Low Target$1.43
Based on 40 analysts
Latest News & Updates
🚀
Barron’s·2h ago
BIONEXUS GENE LAB CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift BGLC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
BIONEXUS GENE LAB CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.